• SPX
  • $5,980.10
  • -0.09 %
  • -$5.28
  • DJI
  • $43,947.52
  • -0.02 %
  • -$10.68
  • N225
  • $38,535.70
  • -0.48 %
  • -$185.96
  • FTSE
  • $8,072.35
  • 0.52 %
  • $42.02
  • IXIC
  • $19,201.90
  • -0.15 %
  • -$28.84
Calithera Biosciences, Inc. (CALA) Stock Price, News & Analysis

Calithera Biosciences, Inc. (CALA) Stock Price, News & Analysis

Currency in USD Disclaimer

$0.01

-$0

(16.67%)

Day's range
$0.01
Day's range
$0.01
50-day range
$0.0001
Day's range
$0.05
  • Country: US
  • ISIN: US13089P5070
52 wk range
$0
Day's range
$0.12


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -28.76
  • Piotroski Score 2.00
  • Grade Market Perform
  • Symbol (CALA)
  • Company Calithera Biosciences, Inc.
  • Price $0.01
  • Changes Percentage (16.67%)
  • Change -$0
  • Day Low $0.01
  • Day High $0.01
  • Year High $0.12

Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule compounds for tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company offers INCB001158, an orally bioavailable arginase inhibitor of arginase that is in Phase 1/2 clinical trial for the treatment of hematology and oncology. It is developing CB-280, an oral arginase inhibitor that has completed Phase 1b clinical trial for the treatment of cystic fibrosis and chronic airway infection; and ATG-037, an orally-bioavailable small molecule inhibitor of CD73, as well as CB-668, an orally administered inhibitor of the enzyme IL4I1. The company has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare. It also has clinical trial collaboration with Pfizer to evaluate Pfizer's PARP inhibitor talazoparib and CDK4/6 inhibitor palbociclib, each in combination with telaglenasta. In addition, the company has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of INCB001158, a small molecule arginase inhibitor for the treatment of hematology and oncology; and a license agreement with Antengene Corporation Ltd. for the development and commercialization of CB-708. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 11/12/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $2.00
  • High Stock Price Target $2.00
  • Low Stock Price Target $2.00
  • Potential Upside/Downside N/A
  • Consensus Rating Buy
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$7.94
  • Trailing P/E Ratio 0
  • Forward P/E Ratio 0
  • P/E Growth 0
  • Net Income $-18,866,000

Income Statement

Quarterly

Annual

Latest News of CALA

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.